FIGURE 3 | The growth potential of the irritable bowel syndrome market.
From the following article:
Ted T. Ashburn & Meera S. Gupta
Nature Reviews Drug Discovery 5, 99-100 (February 2006)
doi:10.1038/nrd1961
As recently as the 1960s, the only treatment options available for patients with hypertension were diuretics, such as trichlormethiazide and the anti-adrenergic reserpine. Since then several new drug classes for this disease have been introduced and also several agents within each of these classes. Similarly, the only treatment available for gastroesophageal reflux disease (GERD) until recently were oral antacids, which have been used since the time of ancient Greece. However, today four drug classes are marketed for GERD and also several drugs within each of these classes. Despite the apparent maturity of these markets, novel approaches continue to be pursued.
Download file
If the slide opens in your browser, select "File > Save As" to save it.
